At the moment, Sangamo Therapeutics, Inc. The firm owned 206,563 shares of the biopharmaceutical company's stock after selling 73,549 shares during the period.
Sangamo shares have more than quadrupled since the beginning of the year.
Other large investors also recently modified their holdings of the company. Geode Capital Management LLC increased its position in Sangamo Therapeutics by 3.1% during the first quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company's stock valued at $1,263,000 after buying an additional 30,000 shares during the period. (NYSE:TDS) traded up 2.92% in the last session while performance was up 26.07% in the last five days.
Sangamo Therapeutics (NASDAQ SGMO) traded up $1.15 during mid-day trading on Friday, reaching $13.45. (SGMO) has 83.61M billion shares outstanding. The stock was sold at an average price of $10.44, for a total transaction of $119,788.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William R. Ringo sold 31,000 shares of the business's stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $15.25, for a total value of $228,750.00. The disclosure for this sale can be found here. The portion of a company's profit allocated to each outstanding share of common stock was $6.29 a share in the trailing twelve months.
Looking forward, the company's quarterly earnings are expected to come at -$0.03 in the three months through December 2017 and in the quarter ending March 2018, reflecting -40% and 302627.3% growth, respectively.
Sangamo Therapeutics, Inc. has a one year low of $2.65 and a one year high of $17.06. Sangamo Therapeutics (NASDAQ:SGMO) has a Return on Assets (ROA) of -30.7.
In the most updated research from a number of analysts on Wall Street, the company gets 4 Buys and 0 Sell among 6 analysts. Sangamo Therapeutics Inc (NASDAQ:SGMO) has risen 29.78% since November 11, 2016 and is uptrending.
Sangamo Therapeutics, Inc. most recently reported earnings per share (EPS) of -$0.17 for the June 2017 versus -$0.38 in the same quarter past year, representing -55% growth.
According to sentiments of 2 analysts the mean estimates of short term price target for the company's stock is marked at $6. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. Sangamo Therapeutics's quarterly revenue was up 333.0% on a year-over-year basis. analysts forecast that Sangamo Therapeutics will post -0.85 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: "Sangamo Therapeutics, Inc". Voya Inv Management Limited Liability Corp reported 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). If you happen to be reading this article on another website, it was stolen and illegally republished in violation of United States of America and worldwide copyright law.
At the moment, the top institutional investor at Sangamo Therapeutics, Inc. Zacks Investment Research lowered shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, July 18th. Jefferies Group LLC reiterated a "buy" rating and set a $18.00 target price on shares of Sangamo Therapeutics in a report on Thursday, September 14th. Wells Fargo initiated the shares of SGMO in report on Friday, December 4 with "Outperform" rating. Piper Jaffray Cos. cut shares of Sangamo BioSciences from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $9.00 to $5.00 in a report on Wednesday, October 19th.
Among 3 analysts covering ProSiebenSat.1 (OTCMKTS:PBSFF), 2 have Buy rating, 1 Sell and 0 Hold. The most optimistic analyst sees the stock reaching $7 while the most conventional predicts the target price at $5.
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Firm is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy.